Medgenics, the developer of technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, reported that its wholly owned subsidiary Medgenics Medical Israel was awarded a government grant of up to NIS 8.1 million (approximately $2.2 million) from the Office of the Chief Scientist in Israel. The grant will be used to cover R&D expenses to support further clinical development of the company’s proprietary tissue-based Biopump platform technology. Medgenics holds offices in San Francisco, California and Misgav, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments